This is what they do;
Stock Bashing: "This scheme is usually orchestrated by savvy online message board posters (a.k.a. "Bashers") who make up false and/or misleading information about the target company in an attempt to get shares for a cheaper price. This activity, in most cases, is conducted by posting libelous posts on multiple public forums. The perpetrators sometimes work directly for unscrupulous Investor Relations firms who have convertible notes that convert for more shares the lower the bid or ask price is; thus the lower these Bashers can drive a stock price down by trying to convince shareholders they have bought a worthless security, the more shares the Investor Relations firm receives as compensation. Immediately after the stock conversion is complete and shares are issued to the Investor Relations firm, consultant, attorney or similar party, the basher/s then become friends of the company and move quickly to ensure they profit on a classic Pump & Dump scheme to liquidate their ill gotten shares. ...........................GLTA
My guess is they fall under the mgmt of Dr.Pavco..............taken from website;
Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck & Co., Inc. for $1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna-027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirna’s alliance with Allergan. in part.
I follow the science hanna, and happen to be a strong admirer of mgmt as you know. As far as predicting price targets I would refer to hofno, he seems to have a good idea as to the equation of pt vs. market potential. read his recent posts as to risk/reward. makes sense.....
Three analysts that cover RXI have a median I yr at $9. I feel that if we get good P2 and the mkt for 109 is even close to $1b, I'd triple that estimate. Lot of ifs still, but; You know how I feel about the good doctor......................GLTA
Not sure your assessment of cornea would fall under dermal bio. I'll take a wild stab at psoriasis or possibly other skin ailments other than scarring. skin cancers another possibility?
Dermatology is the specialty of both Cauwenbergh and Pavco, and Frost for that matter. Meaning only guessing on this end.
Perhaps bringing up any one of the compounds of the 12 families of RNAi compounds inherited from Opko.
waterboy-waterway your new moniker doesn't help you. You are just to stupid to know how to scare people. I could show you guys how to do it, but it would bother me. You see I don't like people who lie and cheat attempting to take advantage of others, #$%$, know what I mean?
A very novel approach to risk assessment. I,m not very familiar with the formula of mkt share vs pps but your equations do make sense. Must admit it did not immediately sink in though.
The validation of an entire platform of therapies may put this in the forefront of RNAi, and there are none better suited to the task than Cauwenbergh and Pavco.....................looking good.
nearly 1.8M traded. Even with the admitted % of traders now, solid accumulation.
Could it be this little company is finally getting some attention?...................GLA
Positive news validated the "platform" based upon rx-109, in addition. It will put RXI on a new level of progression. They did not lease 3X the previous space for no reason. All looking good hofno.
"On time and on budget". Just like he said................GLTA
OK I will, you're very stupid waterway. I'd find a new line of work if I were you. You just don't cut it as as stock analyst.
You're too stupid.
Boy are you stupid. why would Dr. C. advertise that he's sharing date at the R&R conference, so he can give the bad news in front of everybody?
Your the dumbest of dumb.
MARLBOROUGH, Mass., Sept. 3, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 12:05 p.m. EST. Dr. Cauwenbergh will provide a corporate update which will include data on novel targets and compounds in the Company's dermatology franchise as well as provide interim data for their first Phase 2a trial RXI-109-1301.
Now read the last sentence again.............GLTA